Barclays analyst Glen Santangelo lowered the firm’s price target on Waystar (WAY) to $42 from $50 and keeps an Overweight rating on the shares following a transfer of coverage. The firm also started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar initiated with a Hold at Freedom Capital
- Waystar initiated with an Outperform at BMO Capital
- BMO Capital Recommends Buy for Waystar Holding Corp. Due to Strong Market Position and Growth Potential
- DraftKings downgraded, Instacart upgraded: Wall Street’s top analyst calls
- Waystar initiated with a Buy at Needham